|
Market Closed -
Nasdaq
09:30:00 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 0.1052 USD | -10.09% |
|
-34.25% | -87.62% |
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-13 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 2.16M 1.93M 1.8M 1.64M 3.08M 208M 3.1M 21.72M 8.45M 106M 8.12M 7.94M 342M | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 24.02M 21.43M 19.96M 18.16M 34.21M 2.31B 34.46M 241M 93.84M 1.18B 90.16M 88.21M 3.79B | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.46% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | -15.63% | ||
| 1 month | -31.24% | ||
| 3 months | -28.39% | ||
| 6 months | -13.06% | ||
| Current year | -87.62% |
| 1 week | 0.11 |  | 0.12 |
| 1 month | 0.11 | | 0.16 |
| 3 years | 0.05 | | 8.48 |
| 5 years | 0.05 | | 12.3 |
| 10 years | 0.05 | | 88.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 2025-07-20 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 2025-05-15 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 2016-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 2013-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 2023-03-20 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 2023-03-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.09% | -34.25% | -94.31% | -96.24% | 2.41M | |
| +0.02% | -3.52% | +36.11% | +111.11% | 1,019B | |
| -1.21% | -6.99% | +34.08% | +60.96% | 617B | |
| +1.12% | -0.20% | +13.62% | +80.24% | 464B | |
| -3.30% | -6.15% | +56.45% | +34.69% | 356B | |
| +0.93% | -1.83% | +21.65% | +41.43% | 333B | |
| +0.12% | -4.05% | +10.70% | +33.53% | 267B | |
| -0.89% | -5.83% | -7.00% | +7.91% | 244B | |
| -0.01% | -3.62% | +35.28% | +52.02% | 218B | |
| -0.08% | -4.98% | +28.34% | +93.61% | 179B | |
| Average | +0.21% | -3.74% | +13.49% | +41.93% | 410.8B | |
| Weighted average by Cap. | +0.44% | -3.63% | +28.50% | +68.49% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 28.54M 25.46M 23.72M 21.58M 40.65M 2.75B 40.95M 287M 111M 1.4B 107M 105M 4.51B | 20.71M 18.48M 17.21M 15.67M 29.5M 1.99B 29.72M 208M 80.93M 1.02B 77.75M 76.08M 3.27B |
| Net income | -39.26M -35.02M -32.63M -29.69M -55.92M -3.78B -56.33M -394M -153M -1.93B -147M -144M -6.2B | -48.06M -42.87M -39.94M -36.35M -68.45M -4.63B -68.96M -483M -188M -2.36B -180M -177M -7.59B |
| Net Debt | 6.05M 5.4M 5.03M 4.58M 8.62M 583M 8.68M 60.76M 23.64M 297M 22.71M 22.22M 956M | 21.85M 19.5M 18.16M 16.53M 31.13M 2.1B 31.36M 219M 85.39M 1.07B 82.04M 80.27M 3.45B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-05 | US$0.1052 | -10.09% | 201 |
| 26-10-02 | US$0.1170 | 0.00% | 1,025 |
| 26-10-01 | US$0.1170 | - | 3,259 |
| 26-09-30 | US$0.000000 | -100.00% | 126 |
| 26-09-29 | US$0.1147 | -8.01% | 273 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CASIF Stock
- CASI Stock
Select your edition
All financial news and data tailored to specific country editions
